Literature DB >> 26857258

[Standard therapy of tuberculosis].

R Otto-Knapp1,2, K Schenkel3, T Bauer3,4.   

Abstract

Based on the results of studies from the 1960s-1980s the current four drug combination therapy was established as standard or short course tuberculosis therapy worldwide. The regional epidemiology and the often unique conditions within a national health system create the need for specific adjustments. Over the last years these were realized by the German central committee against tuberculosis (DZK) in the recommendations for tuberculosis therapy. Because of the recent development of migration into Germany from countries with higher tuberculosis incidences an increase in tuberculosis cases is to be expected. The expected increase in tuberculosis cases will lead to more contact with tuberculosis patients even in the outpatient setting. New S2k guidelines guided by the Association of the Scientific Medical Societies in Germany (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, AWMF) for the treatment of tuberculosis for children and adults are under development. Before the release of the comprehensive guidelines, practical evidence for the diagnosis and treatment of uncomplicated tuberculosis is summarized in this document to meet the challenges of the recent developments.

Entities:  

Keywords:  Adjuvant Therapy; Drug monitoring; Epidemiology, tuberculosis; Medication adherence; Patient education

Mesh:

Substances:

Year:  2016        PMID: 26857258     DOI: 10.1007/s00108-016-0031-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  12 in total

1.  Treatment of tuberculosis: update 2010.

Authors:  W W Yew; C Lange; C C Leung
Journal:  Eur Respir J       Date:  2010-09-16       Impact factor: 16.671

2.  Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor.

Authors:  Shashank Gupta; Sandeep Tyagi; Deepak V Almeida; Mariama C Maiga; Nicole C Ammerman; William R Bishai
Journal:  Am J Respir Crit Care Med       Date:  2013-09-01       Impact factor: 21.405

Review 3.  Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Authors:  Abdullah Alsultan; Charles A Peloquin
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

Review 4.  An official ATS statement: hepatotoxicity of antituberculosis therapy.

Authors:  Jussi J Saukkonen; David L Cohn; Robert M Jasmer; Steven Schenker; John A Jereb; Charles M Nolan; Charles A Peloquin; Fred M Gordin; David Nunes; Dorothy B Strader; John Bernardo; Raman Venkataramanan; Timothy R Sterling
Journal:  Am J Respir Crit Care Med       Date:  2006-10-15       Impact factor: 21.405

5.  Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.

Authors:  Rodney Dawson; Andreas H Diacon; Daniel Everitt; Christo van Niekerk; Peter R Donald; Divan A Burger; Robert Schall; Melvin Spigelman; Almari Conradie; Kathleen Eisenach; Amour Venter; Prudence Ive; Liesl Page-Shipp; Ebrahim Variava; Klaus Reither; Nyanda E Ntinginya; Alexander Pym; Florian von Groote-Bidlingmaier; Carl M Mendel
Journal:  Lancet       Date:  2015-03-18       Impact factor: 79.321

6.  [Recommendations for therapy, chemoprevention and chemoprophylaxis of tuberculosis in adults and children. German Central Committee against Tuberculosis (DZK), German Respiratory Society (DGP)].

Authors:  T Schaberg; T Bauer; S Castell; K Dalhoff; A Detjen; R Diel; U Greinert; B Hauer; C Lange; K Magdorf; R Loddenkemper
Journal:  Pneumologie       Date:  2012-02-10

7.  Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial.

Authors:  Christian Lienhardt; Sharlette V Cook; Marcos Burgos; Victoria Yorke-Edwards; Leen Rigouts; Gladys Anyo; Sang-Jae Kim; Amina Jindani; Don A Enarson; Andrew J Nunn
Journal:  JAMA       Date:  2011-04-13       Impact factor: 56.272

8.  Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment.

Authors:  Anna K Coussens; Robert J Wilkinson; Yasmeen Hanifa; Vladyslav Nikolayevskyy; Paul T Elkington; Kamrul Islam; Peter M Timms; Timothy R Venton; Graham H Bothamley; Geoffrey E Packe; Mathina Darmalingam; Robert N Davidson; Heather J Milburn; Lucy V Baker; Richard D Barker; Charles A Mein; Leena Bhaw-Rosun; Rosamond Nuamah; Douglas B Young; Francis A Drobniewski; Christopher J Griffiths; Adrian R Martineau
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-04       Impact factor: 11.205

9.  Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT Study [Supplementary Cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis'.

Authors:  Nawal Salahuddin; Farheen Ali; Zahra Hasan; Nisar Rao; Masooma Aqeel; Faisal Mahmood
Journal:  BMC Infect Dis       Date:  2013-01-19       Impact factor: 3.090

10.  Mycobacterium tuberculosis is extraordinarily sensitive to killing by a vitamin C-induced Fenton reaction.

Authors:  Catherine Vilchèze; Travis Hartman; Brian Weinrick; William R Jacobs
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.